IP Library Granted Patent US 9,932,404
Granted Patent B2
US 9,932,404 · App. 15/345,860 · Granted Apr 3, 2018

Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist

Inventors: Mark Cunningham (Kennett Square, PA); Yiqing Feng (Wayne, PA); Katharine Heeringa (Wayne, PA); Jinquan Luo (Malvern, PA); Robert Rauchenberger (Martinsried, DE); Mark Rutz (Martinsried, DE); Lani San Mateo (Devon, PA); Robert Sarisky (Lansdale, PA); Raymond Sweet (Bryn Mawr, PA); Fang Teng (Chesterbrook, PA); Alexey Teplyakov (Phoenixville, PA); Sheng-Jiun Wu (Broomall, PA)
Assignee: Janssen Biotech, Inc.
C07K16/2896A61K39/3955C07H21/04C07K16/28C12N15/117A61K2039/505C07K14/705C07K16/2863C07K2317/21C07K2317/24C07K2317/33C07K2317/34C07K2317/52C07K2317/55C07K2317/56C07K2317/565C07K2317/76C07K2317/92C07K2317/94C12N5/10C12N5/12C12N15/63C12N2310/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,932,404
App. No.
15/345,860
Granted
Apr 3, 2018
Kind
B2
Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Claims (18)

1. A method of reducing a clinical symptom of a respiratory viral infection in an individual, the method comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to the individual for a time sufficient to reduce the clinical symptom, wherein the antibody binds toll-like receptor 3 (TLR3) amino acid residues K416, K418, L440, N441, E442, Y465, N466, K467, Y468, R488, R489, A491, K493, N515, N516, N517, H539, N541, 5571, L595, and K619 of SEQ ID NO: 2.

2. The method of claim 1 , wherein the viral infection is influenza A virus infection.

3. The method of claim 1 , wherein the antibody is fully human.

4. The method of claim 1 , wherein the antibody is human adapted.

5. The method of claim 1 , wherein the antibody is conjugated to poly(ethylene glycol).

6. The method of claim 1 , wherein the antibody is of an IgG4 isotype.

7. The method of claim 1 , wherein the antibody comprises an Fc domain comprising S229P, P235A or L236A substitutions.

8. The method of claim 1 , wherein the viral infection is caused by a double-stranded RNA (dsRNA) virus or a virus that has dsRNA as a replication intermediate.

9. The method of claim 1 , wherein the clinical symptom is inflammation.

10. A method of reducing a clinical symptom of a respiratory viral infection in an individual, the method comprising administering a therapeutically effective amount of an isolated antibody or fragment thereof to the individual for a time sufficient to reduce the clinical symptom, wherein the isolated antibody comprises a heavy chain variable region and a light chain variable region or fragment thereof and the isolated antibody heavy chain variable region Chothia residues W33, F50, D52, D54, Y56, N58, P61, E95, Y97, Y100, and D100b and the isolated antibody light chain variable region Chothia residues Q27, Y32, N92, T93, L94, and S95 bind toll-like receptor 3 (TLR3) that has the amino acid sequence shown in SEQ ID NO: 2.

11. The method of claim 10 , wherein the viral infection is influenza A virus infection.

12. The method of claim 10 , wherein the antibody is fully human.

13. The method of claim 10 , wherein the antibody is human adapted.

14. The method of claim 10 , wherein the antibody is conjugated to poly(ethylene glycol).

15. The method of claim 10 , wherein the antibody is of an IgG4 isotype.

16. The method of claim 10 , wherein the antibody comprises an Fc domain comprising S229P, P235A or L236A substitutions.

17. The method of claim 10 , wherein the viral infection is caused by a double-stranded RNA (dsRNA) virus or a virus that has dsRNA as a replication intermediate.

18. The method of claim 10 , wherein the clinical symptom is inflammation.

Assignments (2)
CHANGE OF NAME Recorded Feb 15, 2018
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 045346/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2018
From: CUNNINGHAM, MARK; FENG, YIQING; HEERINGA, KATHARINE; LUO, JINQUAN; SAN MATEO, LANI; SARISKY, ROBERT; SWEET, RAYMOND; TENG, FANG; TEPLYAKOV, ALEXEY; WU, SHENG-JIUN; RAUCHENBERGER, ROBERT; RUTZ, MARK
To: CENTOCOR ORTHO BIOTECH INC.
Reel/Frame 045346/0757 →
Continuity (8)
Division 13973187 · Aug 22, 2013
Division 12770147 · Apr 29, 2010
Continuation In Part 12609675 · Oct 30, 2009
Provisional Application 61109974 · Oct 31, 2008
Provisional Application 61161860 · Mar 20, 2009
Provisional Application 61165100 · Mar 31, 2009
Provisional Application 61173686 · Apr 29, 2009
Related Publication 20170058041A1 · Mar 2, 2017